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Abstract 
BACKGROUND: Cause of recurrence of breast cancer is multifactorial. Also, the occurrence of breast cancer in 
Asian patients has some different factors from the recurrence of breast cancer in western countries.  
AIM: This study aims to determine the prognostic factors of local-regional recurrence in patients with operable 
breast cancer in Asia. 
METHODS: The authors conducted a meta-analysis of published research articles published in an online 
database of PubMed, ProQuest and EBSCO between January 2000 and July 2018. Pooled risk ratios (RR) were 
calculated using fixed and random-effect models. Data were processed by using Review Manager 5.3 (RevMan 
5.3). 
RESULTS: This study reviewed 879 articles. There were 11 studies conducted a systematic review then 
continued by meta-analysis of relevant data with total patients involved were 5,213 patients. The prognostic 
factors found of local-regional recurrence in patients with operable breast cancer were Nodal (N) stage with the 
highest risk ratio (RR = 6.35 [95% CI 3.78-10.67]) followed by HER2 positive (RR = 2.14 [95% CI 1.16-3.97]), 
stage of cancer (RR = 1.82 [95% CI 1.44-2.31]), tumor size (RR = 1.55 [95% CI 1.04-2.31]), tumor grade (RR = 
1.43 [95% CI 1.23-1.65]), PR status (RR = 0.65 [95% CI 0.48-0.88]) and the least was ER status (RR = 0.60 [95% 
CI 0.39-0.91]). Homogeneity of variance was found in N stage, tumor size and tumor grade for recurrence of 
operable breast cancer. 
CONCLUSION: This meta-analysis confirmed the correlation of N stage, HER2, stage of cancer, tumour size, 
tumour grade, ER and PR status with recurrence in patients with operable breast cancer in Asia. 
 
 
 
 
 
 
 
 
Introduction 
 
Breast cancer, the most common cancer in 
women, is highly heterogeneous with various clinical 
courses and outcomes [1], [2]. The disease 
recurrence and prolong survival have been reduced 
by several proven adjuvant systemic therapies, 
including chemotherapy, hormonal treatment, and 
anti-HER2 (human epidermal receptor). Breast 
cancers are classified into genomically defined 
subgroups, including subtypes: luminal A, luminal B, 
HER2+, and triple-negative (TN) tumours. Clinical 
courses, patterns of metastasis, and prognosis of 
these subgroups may be various. Most relapses 
happen during the first 5 years after diagnosis, even 
though the late recurrence of luminal breast cancer 
has been reported. 
Breast cancer may recur 5-10 years after first 
treatment. High-bulk disease, high proliferative index, 
and HER2-positive malignancies correlated to 
recurrence earlier than 10 years, whereas 
progesterone receptor-positive (PR+) group was 
associated with relapse later than 10 years [3], [4]. 
The term of local-regional recurrence refers to 
recurrence either in ipsilateral breast structure after 
lumpectomy, in chest wall recurrence after 
mastectomy or recurrence in axillary or 
supraclavicular lymph nodes (less common 
infraclavicular and/or internal mammary nodes) 
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Approximately, local recurrence develops in 10-15% 
of stage I-II of breast cancer after breast-conserving 
surgery and 10-20% chest wall recurrence in the 
cancer stage I-IIIA after mastectomy [4]. 
Annual follow-up visits are usually scheduled 
for patients who have five disease-free years or 
completed hormonal treatment. Some of those 
patients develop rapid and extensive metastasis 
during the follow-up intervals; with few of these 
patients can not undergo chemotherapy due to organ 
dysfunction or unwell performance status as a result 
of systemic metastasis. In spite of the decrease of 
recurrence risk by adjuvant chemotherapy in the first 5 
years, the effect of the therapy beyond 5 years is still 
unknown. Patients with estrogen receptor-positive 
(ER+) breast cancer have benefited from adjuvant 
tamoxifen, with the greatest benefit is in the first 4 
years and an additional decline of recurrence risk 
carryover for more than 5 years [5]. Tamoxifen use 
extended to 10 years in women with early-stage 
breast cancer reportedly reduces the risk of late 
recurrence [6]. 
The cause of recurrence of breast cancer is 
multifactorial. Nowadays, several risk factors for 
breast cancer recurrence have been reported. The 
risk factors known are age, menopausal status, 
clinical T (tumour), clinical N (nodal involvement), LN 
(lymph-node), lymphovascular invasion, margin 
status, histologic grade, nuclear grade, hormonal 
status, HER2 status, chemotherapy, and antihormonal 
treatment [6], [7]. Also, the occurrence of breast 
cancer in Asian patients has some different factors 
from the recurrence of breast cancer in western 
countries.  
This study determined prognostic factors of 
local-regional recurrence in patients with operable 
breast cancer in Asia by performing a meta-analysis 
study in which the conclusion had drawn have better 
accuracy. The result in this study will be useful and 
assist physicians in determining prognostic factor of 
recurrence in Asian patients with operable breast 
cancer. 
 
 
Material and Methods 
 
Study design and research sample 
This research was a quantitative study 
performed by using meta-analysis study design. The 
meta-analysis followed PRISMA (Preferred Reporting 
Items for Systematic Reviews and Meta-Analysis) 
Statement [8]. Meta-analysis was used to find 
prognostic factors of local-regional recurrence in 
patients with operable breast cancer in Asia. The 
research samples consisted of published research 
articles published in online article databases of 
PubMed, ProQuest and EBSCO between January 
2000 and July 2018. 
 
Operational definitions 
The variables of this study included several 
independent variables of prognostic factors, i.e: age, 
menopausal status, clinical T (tumor), clinical N (nodal 
involvement), LN (lymph-node), lymphovascular 
invasion, margin status, histologic grade, nuclear 
grade, hormonal status, HER2 status, chemotherapy, 
and antihormonal treatment; and a dependent 
variable, i.e: local-regional recurrence of operable 
breast cancer.  
 
Research procedure  
This study was conducted by collecting data 
through the identification of published research 
articles on prognostic factors of recurrence in patients 
with operable breast cancer in Asia in online article 
databases of PubMed, ProQuest and EBSCO (Figure 
1). 
 
Figure 1: Flow diagram research procedure 
 
Identification process of 913 articles was held 
by identifying the title of the articles, continued by 
abstract and full-text review of the articles. The article 
excluded if: (a) unrelevant to subject outcome, (b) the 
methods was neither case-control nor cohort study (c) 
the data provided in the results section of the article 
was insufficient for extraction and (d) duplicate 
studies. 
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Data collection technique 
The search was limited to English language 
articles. The article type was limited to research 
articles. The research subject was limited to research 
involved human subject. The time of publication was 
limited for January 2000 to July 2018 period. The 
abstract of articles with relevant title continued to 
review process, and the articles with the irrelevant title 
were excluded. After that, articles with relevant 
abstract were continued to be reviewed in full-text, 
while the others were excluded. The inclusion criteria 
of the sample included published research on 
prognostic factors of recurrence in patients with 
operable breast cancer in Asia. The exclusion criteria 
were either the research was not available in the full-
text form, or the criteria were not satisfied or if the 
information provided was insufficient for data 
extraction. These data were obtained from the 
articles: name of the first author and publication date, 
study location, study type, total samples and risk 
factors identified. 
The information fulfilled criteria of inclusion 
from the studies obtained were extracted carefully by 
two independent investigators by a standardised 
protocol. Three other investigators resolved the 
disagreements. Quality assessment was performed 
by using the Newcastle – Ottawa Quality 
Assessment Scale (NOS) and studies with a NOS 
score ≥ 7 were considered as high quality [9]. 
Table 1: Systematic review of prognostic factors for local-
regional recurrence in operable breast cancer patients in Asia 
First Author, Year Region Type of Study Number of 
Samples 
Risk Factors NOS 
Elkum et al [10] Saudi Arabia Prospective 867 Grade 8 
Son et al. [11] South Korea Prospective 523 Stage 7 
Tanioka et al. [12] Japan Prospective 88 HER2, axillary 
lymph nodes 
7 
Chen et al [13] China Retrospective 540 Positive nodes 7 
Akbari et al [14] Iran Prospective 258 LVI, stage 7 
Song et al. [15] South Korea Prospective 95 Stage, grade, 
p53, Ki67 
7 
Ahn et al. [16] South Korea Prospective 677 N stage, grade, 7 
Wei et al [17] China Prospective 1498 Stage, tumor 
size, ER, PR, 
HER-2 
8 
Wangchinda and 
Ithimakin [18] 
Thailand Retrospective 300 Tumour size, N 
stage, Grade, 
ER, HER2 
7 
Ditsatham et al. [7] Thailand Retrospective 185 ER status, PR 
status 
7 
Ahmadi et al [19] Iran Retrospective 182 Grade, ER, PR 
status 
7 
NOS, Newcastle-Ottawa Quality Assessment Scale. 
 
 
Data analysis 
The analysis was conducted to obtain the 
value of pooled risk ratio as the combined risk ratio 
value from the collected research. Data analysis was 
held by using the Mantel-Haenszel method with a 
fixed effect model and the DerSimonian-Laird random-
effect model. Meta-analysis was carried out by using 
Review Manager 5.3. 
 
 
Results 
 
The selection of studies was conducted to 
identify 11 studies related to prognostic factors of 
recurrence in patients with operable breast cancer in 
Asia with total sample of 5,213 patients [7], [10], [11], 
[12], [13], [14], [15], [16], [17], [18], [19] (Table 1). 
We found 11 studies through the systematic 
review (7 cohort study and 4 case-control) which then 
analysed by meta-analysis. The research variables 
analysis was based on the systematic review that has 
been done included stage of cancer, grade of the 
tumour, HER2, tumour size, N stage, ER and PR 
status (Figure 2). 
 
Figure 2: Forest plots prognostic factors of local-regional recurrence 
in patients with operable breast cancer in Asia 
 
It was shown in Figure 2, based on prognostic 
factors known, N stage has the highest risk ratio (RR 
= 6.35 [95% CI 3.78-10.67]) followed by HER2 (RR = 
2.14 [95% CI 1.16-3.97]), stage of cancer (RR = 1.82 
[95% CI 1.44-2.31]), tumor size (RR = 1.55 [95% CI 
1.04-2.31]), tumor grade (RR = 1.43 [95% CI 1.23-
1.65]), PR status (RR = 0.65 [95% CI 0.48-0.88]) and 
ER status (RR = 0.60 [95% CI 0.39-0.91]). Funnel 
plots was performed to identify publication bias among 
publication on recurrence in patients with operable 
breast cancer in Asia (Figure 3). 
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Figure 3: Funnel plots prognostic factors of local-regional 
recurrence in patients with operable breast cancer in Asia 
 
Figure 3 shows that N stage, stage of cancer, 
tumour size and tumour grade have homogeneity of 
variance for recurrence of operable breast cancer 
resulted by the symmetrical plot based on the vertical 
line which means if the analysis conduct on a different 
population, time, place, and conditions, the results will 
be consistent. This is different from HER2, ER and PR 
status. 
 
 
Discussion 
 
Local recurrence is the reemergence of 
tumour in the ipsilateral breast chest wall or overlying 
skin. The incidence of local-regional recurrence after 
mastectomy is 9%-28% in early breast cancer. 
Approximately 40% of isolated local-regional 
recurrences are detected during routine examinations 
in symptomatic or asymptomatic patients. Identifying 
and management of local recurrence is important 
because 30-40% of local-regional recurrence will 
develop distant metastasis. The peak of annual 
hazard for recurrence occurs in 1 to 2 years after 
treatment and then declines slowly after 12 years. 
Therefore, the factors correlated to local-regional 
recurrence are essential to identify to provide 
adequate therapy so that metastasis can be 
prevented. Breast cancer in Asia seems to be different 
from western countries since it occurs at a younger 
age with an average age of 40 to 50 years and with 
smaller breast sizes leading to more difficult 
conservative surgery [20]. 
In this study, we compiled a total of 5,213 
patients from 11 studies (7 cohort study and 4 case-
control) that are appropriate for this systematic review. 
The races included in this study are Arabic, Japan, 
China, Korea and Malay. The basis of prognostic 
factors of recurrence in patients with operable breast 
cancer in Asia, consecutively, are N stage has the 
highest risk ratio (RR = 6.35 [95% CI 3.78-10.67]) 
followed by HER2 (RR = 2.14 [95% CI 1.16-3.97]), 
stage of cancer (RR = 1.82 [95% CI 1.44-2.31]), tumor 
size (RR = 1.55 [95% CI 1.04-2.31]), tumor grade (RR 
= 1.43 [95% CI 1.23-1.65]), PR status (RR = 0.65 
[95% CI 0.48-0.88]) and ER status (RR = 0.60 [95% 
CI 0.39-0.91]). N stage, stage of cancer, tumour size 
and tumour grade have homogeneity of variance for 
recurrence of operable breast cancer. 
The previous study known in Arab population 
has identified that young age (≤ 40) is an independent 
risk factor for relapse in operable Saudi breast cancer 
patients [10]. Another study in Japan found that HER2 
status and axillary metastases are independent 
predictors of recurrence in breast cancer patients [12]. 
In China population, it has been reported that axillary 
lymph nodal status is the only risk factor of 
significant impact on 10-year [13]. In Thailand 
population, ER
+
/PR
+
 and HER2
−
 patients have a 
higher risk of recurrence in later than 5 years, 
especially in patients with high ER titer and low 
nuclear grade. Tumour with larger and node-positive 
have a higher risk of early recurrence [18].  
The first and second influential factor of 
recurrence in breast cancer patients is the 
involvement of axillary lymph nodes and HER-2 
positive, respectively [12]. This systematic review also 
proves that the presence of lymph node metastasis 
plays a significant role as a predictive factor for local 
recurrence. By a report from the United States which 
Saphner et al., reported that the hazard for the 
recurrence is particularly high for those with 4 or more 
involved axillary lymph nodes during the first to 6 
years of follow up as well as those with fewer nodes 
involved [21]. 
Following metastasis to the axillary lymph 
nodes, the HER2 type has the second highest hazard 
rate at local recurrence. The presence of HER2 
positivity will be a major factor in recurrence if patients 
do not receive adjuvant trastuzumab therapy [22]. 
HER2 is transmembrane tyrosine kinase receptor 
regulating cell growth, proliferation. Amplification of 
this gene observed in 15 – 30 % of breast cancer 
patients and is a strong prognostic biomarker for 
aggressive disease. The prominence of HER2 positive 
factors as a second order risk factor in this study is 
interesting since this is different from the risk factor for 
local-regional recurrence of western countries. This 
phenomenon can be explained by the high 
percentage of young age breast cancer in Asia who 
have aggressive behaviour as well as a high 
percentage overexpression of HER2. 
Stage of cancer is strongly correlated with 
tumour size. In this study, it was found that the stage 
and size of the tumour as a third and fourth risk factor 
for the occurrence of local-regional breast cancer 
recurrence in Asia. If the tumour size of more than 2 
cm, positive lymph nodes axillary, histopathologic 
grading, the incidence of recurrence in stage III (25%) 
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is higher than stage I and II (5% and 12%) [23]. Many 
studies have demonstrated a linear correlation 
between the diameter of the primary tumour and both 
the presence of lymph node metastasis and clinical 
outcome. Among node-negative patients, tumour size 
is the only important prognostic factor [24]. 
The estrogen receptor impact in prognosis 
was significant in lymph node-positive patients [10]. In 
the first three years after diagnosis, estrogen receptor 
positivity affects prognosis significantly, but after three 
years this effect is not present. However, estrogen or 
progesterone receptor positive tumours will respond 
better to treatment with anti-estrogen drugs like 
Tamoxifen. A large study conducted in 37000 women 
in 1998 indicated that Tamoxifen treatment in 
estrogen receptor-positive patients would decrease 
recurrence and mortality rate for 47% and 26%, 
respectively [25]. In study patients with negative 
lymph nodes, estrogen receptor positivity has been 
associated with better prognosis [26].  
Type of cancer and its grade, presence of 
tumour emboli, endolymphatic invasion, negative 
estrogen receptor, Increased expression of HER-2 
and positive P53 are all variables that have been 
associated with risk of local recurrence [27]. A study 
reported that early recurrence associated with 
unregulated stress response signalling and certain 
clinical parameters, such as molecular subtypes, 
tumour size, and grade; while late recurrence 
correlated with mesenchymal characteristics of the 
tumour epithelium and gene expression alterations in 
the adjacent tumour stroma [28]. 
Local-regional recurrence may be associated 
with more aggressive tumour biology. Several factors 
have been associated with increased risk for local-
regional recurrence in western. These factors are a 
lymphovascular invasion, young age, increasing 
tumour size, closed or involved margin status, positive 
nodal, high grade, extensive intraductal component, 
multifocal/centric disease, negative hormone 
receptors, lack of adjuvant systemic therapy [23], [27], 
[29]. The NSABP B-06 trial found a 3 times greater 
incidence of distant relapse in patients with local 
recurrence and 2.5 times higher increased risk of 
death. One-third of these patients have synchronous 
distance disease and another one-third subsequently 
develop metastatic disease, so re-staging of the 
patient with local-regional recurrence is important. 
Patients who have nodal recurrence has a higher risk 
than those with chest wall recurrence. Nodal 
recurrence may be a source of distant metastasis or a 
marker of systemic dissemination [30].  
There were a few limitations in this meta-
analysis. First, two studies seemed potentially eligible 
to be included in this meta-analysis, but the full texts 
were not accessible. This issue may raise the 
possibility of selection bias. Second, the number of 
cases sample in one study is relatively small (12), 
which can reduce statistical power. 
Several studies have analysed and compared 
patients who died with the recurrent disease with 
those without recurrent disease. However, less 
attention has been paid to evaluating factors 
associated with the recurrence.  
In conclusion, the development of recurrent 
breast cancer has been investigated as an effort to 
achieve successful breast cancer therapy and better 
clinical outcome as well as more number of breast 
cancer survivors. Loads of the number of follow up 
patients in this large population requires efficient, 
timesaving and cost-effective monitoring. Assessment 
for recurrence risk of the disease could be performed 
by the integration of the anticipated natural history of 
breast cancer based on its anatomic and biologic 
prognostic factors and the anticancer treatment 
administered.  
This analysis confirmed the correlation of N 
stage, HER2, stage of cancer, tumour size, tumour 
grade, ER and PR status with recurrence in patients 
with operable breast cancer. We suggest that these 
patients should have proper treatment and be 
followed up frequently. 
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